title: Thiazolidinediones for treatment of polycystic ovary syndrome.
abstract: OBJECTIVE
  To review the pathophysiology and treatment of polycystic ovary syndrome (PCOS) and the evidence for use of thiazolidinediones in the treatment of this syndrome.
  
  
  METHODS
  We conducted a MEDLINE database search for English-language literature published from January 1966-July 2004. Key terms used were thiazolidinediones, troglitazone, rosiglitazone, pioglitazone, polycystic ovary syndrome, and PCOS. Bibliographies in the relevant articles were reviewed for additional references.
  
  
  METHODS
  All clinical trials were reviewed.
  
  
  RESULTS
  Troglitazone has been evaluated in numerous clinical trials of women with PCOS. These trials provided a body of evidence supporting the efficacy of troglitazone for management of PCOS complications, such as insulin resistance, hyperandrogenism, and anovulation. Due to safety concerns, however, troglitazone is no longer marketed in the United States. Clinical data are emerging regarding the utility of newer, safer thiazolidinediones, such as pioglitazone and rosiglitazone, for this patient population. The available literature provides evidence that these newer agents improve insulin sensitivity, glycemic control, hormone responsiveness, menstrual regularity, and ovulation rates. Pioglitazone and rosiglitazone have been well tolerated in clinical studies and have an improved safety profile in terms of liver toxicity.
  
  
  CONCLUSIONS
  Pioglitazone and rosiglitazone should be considered a second-line treatment alternative to metformin for management of women with PCOS who are resistant to insulin or who are obese.
authors.affiliation: Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma Health Sciences Center College of Pharmacy, Oklahoma City, Oklahoma 73190-5040, USA.
authors.forename: Dena L
authors.initials: DL
authors.lastname: Stout
authors.forename: Susan E
authors.initials: SE
authors.lastname: Fugate
mesh_terms: D000328:Adult; D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D002996:Clomiphene / Q000627:therapeutic use*; D003276:Contraceptives, Oral / Q000627:therapeutic use; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D010060:Ovulation / Q000187:drug effects; D000077205:Pioglitazone; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*; D000077288:Troglitazone
chemical_list: D002839:Chromans; D003276:Contraceptives, Oral; D005300:Fertility Agents, Female; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D002996:Clomiphene; D008687:Metformin; D000077288:Troglitazone; D000077205:Pioglitazone